Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Proceeds from the OO mostly unused one year later

<< Previous

Bullboard Posts

Next >>

Comment by Biobobon Apr 26, 2022 10:31am

108 Views

Post# 34631945

RE:Proceeds from the OO mostly unused one year later

You could add the the spent OO money has amounted to zero shareholder value up to now.. it has been spent on a NASH program that is worth nothing.. because nobody want's to partner with them, because the p3 is really a p2.. because it's worth something if cancer works out basically because they can front the risk themselves. We are late April and now MTD news yet.. again no good surprise yet on that front... whatever again..

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China